D3S-003

D3 Bio (Wuxi) Co., Ltd · Phase 1 active Small molecule

At a glance

Generic name	D3S-003
Sponsor	D3 Bio (Wuxi) Co., Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

D3S-003 CI brief — competitive landscape report
D3S-003 updates RSS · CI watch RSS
D3 Bio (Wuxi) Co., Ltd portfolio CI